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Continuous infusion of macrophage inflammatory
protein MIP-1CX enhances leucocyte recovery and
haemopoietic progenitor cell mobilization after
cyclophosphamide
E Marshall"*, LB Woolford2 and BI Lord2
'CRC Department of Medical Oncology, Christie Hospital, Manchester M20 4BX, UK; 2CRC Department of Experimental Haematology, Paterson Institute for
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Summary Macrophage inflammatory protein la (MIP-1a) inhibits haemopoietic stem cell proliferation. This property has been exploited in a
murine chemotherapy model and has been shown to ameliorate cytotoxic-induced myelosuppression after S-phase-specific cytotoxic
therapy. We have now shown that BB-10010, a stable mutant of MIP-la, (a) is more effective when administered as a continuous infusion
than when bolus injected and (b), when administered via a 7-day infusion during and after cyclophosphamide treatment, results in an earlier
recovery of leucocyte numbers. This effect was accompanied by progenitor cell mobilization into the peripheral blood and included primitive
cells with marrow-repopulating ability (MRA). Maximal mobilization and recovery of leucocytes occurred when MIP-1a was combined with
granulocyte colony-stimulating factor (G-CSF) therapy. The findings suggest that MIP1-a used alone or in combination with G-CSF may allow
delivery of a greater chemotherapy dose intensity as a consequence of both accelerated leucocyte recovery and maintenance of high-quality
mobilized progenitor cells for harvesting and peripheral blood stem cell transplantation.
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Macrophage inflammatory protein la (MIP-la) is an 8-kDa basic
heparin-binding polypeptide that possesses proinflammatory and
reparative activity (Wolpe et al, 1988; Oppenheim et al, 1991). It is
defined as a c-c chemokine on the basis of functional and struc-
tural similarities with other family members, including monocyte
chemotactic activating factor (MCAF) and RANTES (Wolpe et al,
1989; Oppenheim et al, 1991). As a component of the inflamma-
tory response, MIP-la is chemotactic for selected leucocyte
subsets (Wolpe et al, 1989; Oppenheim et al, 1991; Rot et al, 1992;
Schall et al, 1993; Wang et al, 1993). Recently, MIP-la was
described (Graham et al, 1990) as the active component of a
normal bone marrow extract (NBME-IV; Lord et al, 1976), which
inhibits the proliferation ofmultipotential haemopoietic progenitor
cells - stem cells assayed as spleen colony-forming units (CFU-S).
The potential to inhibit stem cell entry into DNA synthesis
provides a novel therapeutic strategy for protecting normal bone
marrow from the cytotoxic effects of chemotherapeutic agents.
This was confirmed following the administration of the S-phase-
specific cytotoxic drugs, hydroxyurea (HU) (Lord et al, 1992) and
cytosine arabinoside (Ara C) (Dunlop et al, 1992). In both models,
MIP-la, administered around the timing of chemotherapy,
ameliorated stem cell loss and resulted in an earlier and more
rapid recovery ofthe stem cell population. Furthermore, protection
of the stem cell compartment was reflected by a significant
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improvement in the kinetics of neutrophil recovery (Dunlop et al,
1992). It now appears that MIP-ax possesses additional properties
to that of simple cell cycle inhibition. Analysis of stem cell (CFU-
S) recovery following HU and MIP-la suggests that MIP-I a may
also modulate the self-renewal and differentiation capacity of the
stem cell population (Lord, 1995). Self-renewal of CFU-S during
the recovery period was 50% higher than during untreated
recovery. The resultant increase in the stem cell pool was then
more than sufficient to offset the complementary reduction in
differentiation rate and thus allowed the more rapid neutrophil
recovery. This, together with the recent report that MIP-la mobi-
lizes haemopoietic progenitor cells (Lord et al, 1995), suggests
that MIP-la may offer further therapeutic benefit when used in
conjunction with the more clinically relevant, non-S-phase-
specific cytotoxic agents.
Evaluation of MIP- la has been hindered by a tendency of the
native protein to undergo aggregation and form high molecular
weight polymers. BB-10010 represents a stable mutant carrying a
single amino acid substitution of Asp26 => Ala with a reduced
tendency to form polymers at physiological pH and ionic strength
(Hunter et al, 1996). The potency of BB-10010 appears to be
similar to native MIP-1a, as judged by receptor binding, calcium
mobilization, thymidine suicide and murine myeloprotective
experiments (Hunter et al, 1996).
Here, we investigate the efficacy ofcontinuous infusion ofMIP-
la (as represented by BB-10010) compared with repeated bolus
injection and demonstrate the beneficial effects of MIP-la on the
recovery kinetics of bone marrow in a murine model of cyclo-
phosphamide-induced bone marrow damage.
*Present address: Clatterbridge Centre forOncology, Bebington, Wirral L63 4JY, UK
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MATERIALS AND METHODS
Animals
Female B6D2FI(C57B1 female x DBA2 male) mice aged 10
weeks were used throughout and all procedures were carried out,
under licence, according to the provisions of the Home Office
Animals (Scientific Procedures) Act, 1986.
Injection of cyclophosphamide
Cyclophosphamide powder (farmtalia Carlo Erba) was dissolved
in isotonic saline. A final dose of 200 mg kg-' was injected
intraperitoneally (i.p.) into preweighed mice.
Cytokines
MIP-lac was kindly supplied by British Biotech Pharmaceuticals
(Oxford, UK) as a non-aggregating genetically engineered variant
of human MIP-Ict (LD78); it is currently known as BB-10010. It
was administered either by subcutaneous injection or by mini-
osmotic pumps (Alzet 2001, CA, USA) implanted subcutaneously
on the backs of mice and delivered at a constant infusion rate of
40 gg per mouse day-' for 3 or 7 days. Recombinant human G-
CSF (Amgen, Thousand Oakes) was injected at a dose of 100
,ug/kg-' subcutaneously every 12 h from day 3 to day 7.
Preparation of cell suspensions
Blood was collected by terminal cardiac puncture under light
anaesthesia (ethrane) and pooled from the various groups ofdonor
mice. Heparin (25 ,u ml-') was used as an anticoagulant. Leucocyte
counts were performed on an automated counter (Sysmex). Bone
marrow cells were harvested by flushing the femur with Fischer's
medium using a 21G needle as previously described (Lord, 1993).
Colony assays
Eight- and 12-day CFU-S (CFU-S8, CFU-S,2) and cells with
marrow-repopulating ability (MRA) were assayed as described in
detail previously (Lord, 1993). Briefly, mice (groups of 20) were
Table 1 Recovery of bone marrow CFU-S after two cycles of sublethal
irradiation using a variable MIP-1 a schedule
Treatment CFU-S per femur
Study I Study II Study III
4.5-Gy y-rays 458 + 51 554 + 58 730 ± 94
7-day MIP-la (0-7)* 1250 + 108 1220 +77 1270 + 127
7-day MIP-1a (1-8) - - 960 + 69
7-day MIP-1 a (7-14) - - 690 + 64
3-day MIP-1 a (0-3) 799 +81 - -
Daily bolus MIP-la - 711 +67
Twice-daily bolus MIP-la - 550 + 56 -
Number of experiments 3 3 3
The results show the means + s.e. of three experiments (a total of nine
experiments in all) for day 10 CFU-S. In all experiments MIP-1awas
administered at a dose of 40 gg per mouse per day. *P < 0.001
(significance level for the combined MIP-1a-treated studies vs combined
controls); **P< 0.05.
exposed to 15.25-Gy 60Co y-ray irradiation at 0.85 Gy h-'. They
were then injected with a freshly prepared suspension of bone
marrow or whole blood. For this, known fractions (1:50-1:400) of
donorfemoral marrow were adjusted to generate approximately 10
colonies per spleen from an injection volume of 0.2 ml. Similarly,
venesected blood (5-100 gl) was diluted to a final volume of
0.2 ml, again to generate approximately ten colonies per spleen in
recipient mice. Eight and 12 days later, ten recipient mice were
killed. Their spleens were fixed and the colonies counted. Cells
with MRA were measured by transplanting haemopoietic tissue
from the donor into an additional five primary irradiated recipient
mice. the transplanted cells were allowed to engraft and develop in
the marrow for 13 days before harvesting and transplanting into a
secondary group of 10 irradiated recipient mice for a CFU-S,2
assay. Results are expressed as CFU-S per femur ± s.e., CFU-S per
ml ofwhole blood ± s.e. or MRA-' ml± s.e. ofwhole blood.
Experimental protocols
Two separate experimental protocols were designed to determine
(a) the optimal schedule of MIP-la delivery using a previously
described model ofrepeated sublethal irradiation (Lord, 1996) and
(b) to investigate the myeloprotective and mobilization properties
ofMIP- ax against cyclophosphamide.
MIP-1la scheduling
Groups of three mice were irradiated with 4.5-Gy whole-body y-
rays. They were administered MIP-la or placebo (phosphate-
buffered saline) either by subcutaneous injection for 7 days or
subcutaneous infusion using an inplanted 7-day mini-osmotic
pump (Alzet 2001). Pumps were inserted under short-acting
anaesthetic (ethrane) at variable time points (3-4 h before or 24 h
or 7 days after irradiation) and removed 3 or 7 days later. After 14
days, this cycle of radiation and treatment was repeated. In all
experiments, groups of three mice were killed at day 14 of treat-
ment cycle 2 and their femoral marrow assayed, in this experi-
ment, forCFU-SIO.
Myeloprotection against cyclophosphamide and
mobilization ofprogenitor cells
Groups ofthree mice received a single i.p. injection of cyclophos-
phamide and the appropriate treatment with MIP-la, G-CSF or
both. MIP-lix was administered for 7 days using a mini-pump
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Figure 1 Bone marrow cellularity after cyclophosphamide with and without
MIP-1a. Results are the means + s.e. of four experiments. *P = 0.05. -,
cyclophosphamide; -U, cyclophosphamide + MIP-1 a
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Figure 3 Leucocyte recovery after cyclophosphamide with and without MIP-
1a. Results are the mean ± s.e. of three experiments. *P < 0.01.-.,
cyclophosphamide; -U-, cyclophosphamide + MIP-la
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Figure 2 (A) CFU-S8 and (B) CFU-S12 per femur after cyclophosphamide
with and without MIP-1a. Results are the means ± s.e. of three experiments.
*P< 0.001. --, cyclophosphamide; U, cyclophosphamide + MIP-1a
inserted under short-acting anaesthetic, approximately 3 h before
cytotoxic treatment. G-CSF (100 gg kg-') was injected subcuta-
neously twice daily from day 3 to day 7. Control mice received
cyclophosphamide only. Femoral bone marrow cellularity and
CFU-S were assayed at time points between days 1 and 14.
Peripheral white blood cell (WBC) counts were made daily from
day 1 to day 10, and the mobilized progenitor cells were assayed
daily from day 4 to day 7 after cyclophosphamide treatment.
Statistical analysis
For each experiment, the means of the respective haematological
parameters were calculated and expressed as means ± standard
errorplotted against time. When appropriate, results were analysed
using a two-sided Student's t-test.
RESULTS
MIP-la scheduling and irradiation
Effect ofcontinuous infusion ofMIP- la on CFU-S recovery
following irradiation
Table 1 shows the results of three separate studies comparing the
effects of timing and bolus vs continuous administration of MIP-
la. Two cycles of 4.5-Gy y-ray irradiation reduced the femoral
CFU-S1o to approximately 10% of normal (458 ± 51) at day 14.
The continuous administration of MIP-la increased the CFU-S
recovery to 1250 (P < 0.001) and 800 CFU-S per femur (P < 0.05)
after 7-day and 3-day infusions respectively (study I, Table 1).
This effect of MIP-la was lost when the same total dose was
administered as a daily (711 CFU-S per femur, P > 0.1) or twice
daily (550 CFU-S per femur, P > 0.1) bolus injection (study II,
Table 1). Finally, the response to MIP-la was dependent on the
timing of administration relative to the myelosuppressive insult
(study III, Table 1). Commencement of 7-day continuous MIP-laX
treatment immediately preceding irradiation conferred maximal
advantage. An attenuated effect (960 ± 69) was evident when the
MIP-la infusion was commenced 24 h after irradiation and was
totally abrogated when administered during the second half of
each cycle (690 ± 64).
Myeloprotection against cyclophosphamide and
mobilization of progenitor cells
Bone marrow recovery
Bone marrow cellularity (Figure 1) showed a similar degree of
suppression at day 1, following cyclophosphamide, irrespective of
additional MIP-la treatment. MIP-Iat did however generate an
Table 2 Total leucocyte count (109 I-1) after cyclophosphamide treatment with and without MIP-1a and/or G-CSF
Treatment Day 4 Day 5 Day 6 Day 7
Cyclophosphamide 2± 0.4 1.6± 0.1 3.1 ± 0.4 7.3± 0.1
Cyclophosphamide + MIP-la 2 ±0.5 2.7± 0.6 6.6 ±0.3** 14.2 +4.0
Cyclophosphamide + G-CSF 1.5 ± 0.2 5.5 ± 1.1* 28.4 ± 1.6*** 26.4 ± 2.5**
Cyclophosphamide + MIP-la + G-CSF 2.3 ± 0.4 14.8 ± 4.7* 26.2 ± 4.9** 26.5 ± 2.3**
Results show the mean ± s.e. of three experiments. *P < 0.05; **P< 0.01; ***P < 0.001.
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concurrent MIP-la developed a similar nadir (2.0 ± 0.5 x 109 1')
but recovered to control leucocyte numbers 1 day earlier (day 6)
(P < 0.01) and overshot twofold by day 7. Leucocyte recovery was
enhanced by the addition of either MIP-la or G-CSF treatment
(Table 2). On its own, MIP-la resulted in only a modest twofold
improvement in the rate of leucocyte recovery compared with
control - normal levels were reached by day 6 compared with day
. - \ >_ ~~~~~~~~~~7 and overshooting to 14.2 x 109 leucocytes 1-1 on day 7 (Figure
U . . *-^ ~^ 3). By comparison, G-CSF normalized leucocyte numbers by day
5 but combined MIP-la and G-CSF accelerated recovery even
4 7 n @ | | further, giving a considerable overshoot of 14.8 ±4.7 1-1 byday 5.
The changes in bone marrow progenitor cell numbers during Day mobilization are shown in Figure 4. CFU-S numbers fell off
parison of bone marrow (BM) and blood CFU-S8 after acutely, after their initial abortive recovery at day 4, to a second
mide. Results are the means of three experiments. d 4,
phamide (blood); -U-, cyclophosphamide + MIP-la nadir which corresponded to the increasing mobilization of pro-
yclophosphamide (BM); -X-, cyclophosphamide + MIP-1a (BM) genitor cells into the peripheral blood. The enhanced mobilization
seen with MIP-1a was reflected by a more rapid reduction in day
8 CFU-S between day 4 and day 6. At day 7, femoral CFU-S
iof recovery at day 4 (12.7 ± 2.9 x 106 per femur vs numbers were similar in both groups (cyclophosphamide 630 ± 40
106 per femur, P = 0.05). Recovery to control numbers vs MIP-la 450 ± 50, P > 0.05) despite a 2.4-fold increase in
te in both groups by day 8. mobilized CFU-S in the MIP-la-treated cohort. _ --.Jr -_ _-- _... Cl --Jr - _ .
The recovery patterns of the day 8 CFU-S and day 12 CFU-S
populations are shown in Figure 2. Cyclophosphamide induced a
rapid fall in both CFU-S populations with a nadir occurring at day
1. By 14 days, both CFU-S8 andCFU-S12 were approaching their
normal numbers (approximately 3500 per femur) having demon-
strated an abortive recovery phase by around day 4. The 8-day
CFU-S were more sensitive to the cytotoxic effects of cyclo-
phosphamide when comparing day 1 survivals in both populations
(CFU-S8 217 ± 37 per femur vs CFU-S12 930 + 70 per femur,
P < 0.001). Co-administration of MIP-la neither provided any
measurable protection to the cells from their initial depletion
nor enhanced their recovery in the first 8 days. Although the
MIP-la-treated groups had consistently higher day 8 and day 12
CFU-S numbers during the later regeneration period, the differ-
ence was small and fell within one standard error of the means
by day 14.
Leucocyte recovery
The total leucocyte counts over 10 days after cyclophosphamide
treatment are shown in Figure 3. For the first 3 days, the WBC
remained in the normal range after which cyclophosphamide treat-
ment produced a short-lasting leucopenia (days 4-6) with a mean
DISCUSSION
MIP- lIx has been shown to protect multipotential haemopoietic
progenitor cells against repeated treatments with S-phase
chemotherapeutic drugs (Dunlop et al, 1992; Lord et al, 1992),
however it remains to be seen whether a similar stratagem will
alleviate the myelosuppressive effects of the more clinically rele-
vant, non-S-phase-specific anti-cancer agents.
We have devised a 7-day schedule ofcontinuous MIP- a (40 jg
per mouse day-') administered via an implanted subcutaneous
pump and inserted before chemotherapy. This dosing schedule was
based on extensive preclinical studies with MIP-la, including a
murine model of MIP-la-induced radioprotection (Lord et al,
1996). In this model, MIP-la attenuated the incremental bone
marrow damage associated with repeated treatments with
sublethal irradiation (450 rads y-rays every 14 days forfourcycles;
Lord et al, 1996). No direct myeloprotection was observed but the
cumulative effects of the enhanced recovery of CFU-Ss became
most notable during the later cycles of treatment. Mechanistically,
the observed response to MIP-la was felt to be most consistent
with an improved self-renewal capability ofthe surviving CFU-Ss,
Table 3 CFU-S ml-' blood after cyclophosphamide treatment with and without MIP-1a and/or G-CSF
Treatment Day 4 Day 5 Day 6 Day 7
CFU-Spermlofblood
Cyclophosphamide 14 + 6 217 ± 63 462 ± 84 612 ± 140
Cyclophosphamide + MIP-1a 318 ± 582 572 ± 129 795 ± 189 1430 ± 542
Cyclophosphamide + G-CSF 220 ± 111 528 ± 108 1911 ± 678 2256 ± 3743
Cyclophosphamide + MIP-1 a + G-CSF 504 ± 474 1032 ± 2211 2303 ± 7201 2371 ± 5451
MRA perml ofblood
Cyclophosphamide 1499 ± 250 2749 ± 900 3925 ± 175 5210 ± 1650
Cyclophosphamide + MIP-1a 8491 ± 14902 16600±6104 21450± 13904 26500± 15004
Cyclophosphamide + G-CSF 6493 ± 3334 11300 ± 13402 17500 ± 30003 24500 ± 25002
Cyclophosphamide + MIP-la + G-CSF 9540 ± 17151 28440 ± 28702 32000 ± 32004 45000 + 50002
Results show the means ± s.e. of three experiments. 1p< 0.05, 2p< 0.01, 3P < 0.02, 4 < 0.001.
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and it therefore suggests a possible role in bone marrow protection
against a wide range of cytotoxic chemotherapy irrespective of
S-phase specificity.
The results reported here confirmed ourearlier findings (Lord et
al., 1996), with enhanced CFU-S numbers in the MIP-la-treated
mice after two cycles despite a lack of direct radioprotection
(- 1200 CFU-S per femur, Table 1). Recovery enhancement was
most evident after the use of a protracted 7-day infusion and,
furthermore, the response was dependent on the timing of
administration, with maximal effects apparent when MIP-la was
commenced before the irradiation treatment. Delaying treatment
for 24 h resulted in an attenuated response, while delaying treat-
ment until the second week of recovery had no effect on CFU-S
regeneration. Bolus injection of MIP- la as a once- or twice-daily
dose also failed to reproduce the advantage conferred by infused
MIP-la, despite the administration of an identical total dose
(40 ,ug per mouse per day).
The results from the cyclophosphamide studies, using an
optimal MIP- la schedule, showed that, as with radiation, a 7-day
infusion ofMIP-1aconferred little or no measurable direct protec-
tion on CFU-S against either the initial degree ofdamage incurred
or against recovery in the first cycle of treatment. In addition,
MIP-1a failed to attenuate the abortive recovery which character-
izes CFU-S kinetics after treatment with cyclophosphamide
(Molineux et al, 1986). A consistent feature of the cyclophos-
phamide model was a modest improvement in CFU-S recovery in
the MIP-la-treated mice (Figure 2). This small recovery advan-
tage, while not statistically significant, is consistent with the obser-
vations during the radiation model (Lord et al, 1996) in which
MIP-la produced only a small benefit after one cycle. The thera-
peutic benefit ofMIP1-a may be more evident when assessed over
multiple cycles ofchemotherapy, as shown in the radiation model
(Lord et al, 1996). However, our own observations and those of
others (Molineux et al, 1986) suggest that repeated cycles of
cyclophosphamide do not result in a useful model of cumulative
bone marrow damage. As aconsequence, we are now investigating
the use ofmore 'stem cell-specific' agents (BCNU and busulphan)
as more representative models of bone marrow damage that can
usefully be protected by MIP-la.
Bone marrow regeneration after cyclophosphamide was associ-
ated with peripheral blood stem cell mobilization, an effect that
was greatly enhanced by concurrent growth factor administration.
This property has been well described and has been exploited
clinically for transplantation purposes (Passos-Coelho et al, 1995).
Lord et al (1995) have recently shown that MIP-la also increases
blood leucocyte numbers and progenitor cell release in mice.
MIP-la preferentially mobilized the more primitive progenitor
cells with marrow-repopulating ability (MRA) and significantly
enhanced the mobilization induced by G-CSF. We now find that
MIP-1a enhances leucocyte recovery following cyclophos-
phamide and that this is mirrored by a significant increase in circu-
lating CFU-S and MRA numbers (Tables 2 and 3). It is noticable
that, with MIP-la, movement from the marrow is more rapid in
the earlier stages and that CFU-S in the circulation are always
higher than in the control group. During the earlierrecovery phase,
mobilization with MIP-Ia exceeded that seen with G-CSF
therapy. Combined treatment with MIP- la and G-CSF resulted in
the most rapid leucocyte recovery and maximal progenitor cell
mobilization, including cells with MRA.
The accelerated leucocyte recovery associated with MIP-la
was similar to that observed in an earlier model using cytosine
arabinoside (Dunlop et al, 1992). In this instance, however, the
recovery advantage occurred despite similar numbers of precursor
cells in the bone marrow. This may represent an earlier release of
bone marrow leucocyte stores, a property that may be common to
all chemotactic factors (Jagel et al, 1992; Laterveer et al, 1995).
Alternatively, it may be the consequence of enhanced differentia-
tion of committed progenitor cells by MIP-la, as has been
suggested by a previous report (Keller et al, 1994). It remains
possible, however, that recovery enhancement is a consequence of
an expanded CFU-S pool, itself the result of a subtle increase in
stem cell self-renewal that is hidden by the simultaneous mobiliza-
tion. Irrespective of the explanation, simultaneous observation of
bone marrow and circulating stem cells shows that bone marrow
parameters when viewed in isolation are not sufficient to allow full
evaluation ofMIP-la's cytoprotective properties.
In conclusion, MIP-1a is a novel factor that has myeloprotec-
tive properties when used in conjunction with S-phase-specific
cytotoxic chemotherapy. We now show that MIP-1a, represented
here as BB-10010, enhances leucocyte recovery and progenitor
cell release after cyclophosphamide treatment. These effects
complement G-CSF and suggest an adjunctive role with all classes
of myelosuppressive chemotherapy, irrespective of their mode of
cytotoxicity. Phase I and phase II clinical studies are now in
progress to evaluate this hypothesis.
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